Considering the efficacy and good tolerability of CDK4/6i, continuing their use beyond progression, either as a rechallenge after drug holiday or by changing the partner agent, is an area of interest with clear pre-clinical rationale both in breast cancer and other solid cancers [23,24]. This evidence concerns the gene CDK4 and breast cancer.